Listed

Liminatus Pharma, Inc.

LIMNNasdaqCIK 1971387HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$1.4m, Q2 FY2026
Net income−$1.4m, Q2 FY2026
Liminatus Pharma, Inc., income statement, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$knot reported714Research and development, period not labelled, three months to 2024-06-30$714.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure357Research and development, period not labelled, three months to 2024-09-30$357.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure0.0Research and development, period not labelled, three months to 2024-12-31$0. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reportednot reportednot reported400Research and development, Q1 FY2026, three months to 2026-03-31$400.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure600Research and development, Q2 FY2026, three months to 2026-06-30$600.0k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Operating income$k(0.2)Operating income, period not labelled, three months to 2024-03-31−$247. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure(909)Operating income, period not labelled, three months to 2024-06-30−$909.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure(543)Operating income, period not labelled, three months to 2024-09-30−$543.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(167)Operating income, period not labelled, three months to 2024-12-31−$167.1k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(264)Operating income, Q1 FY2025, three months to 2025-03-31−$264.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(1,118)Operating income, Q2 FY2025, three months to 2025-06-30−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(701)Operating income, Q3 FY2025, three months to 2025-09-30−$701.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(884)Operating income, Q4 FY2025, three months to 2025-12-31−$884.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(1,101)Operating income, Q1 FY2026, three months to 2026-03-31−$1.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(1,379)Operating income, Q2 FY2026, three months to 2026-06-30−$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Interest expense$knot reported77.2Interest expense, period not labelled, three months to 2024-06-30$77.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure92.7Interest expense, period not labelled, three months to 2024-09-30$92.7k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure106Interest expense, period not labelled, three months to 2024-12-31$106.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure116Interest expense, Q1 FY2025, three months to 2025-03-31$115.5k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure62.3Interest expense, Q2 FY2025, three months to 2025-06-30$62.3k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure19.1Interest expense, Q3 FY2025, three months to 2025-09-30$19.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure19.1Interest expense, Q4 FY2025, three months to 2025-12-31$19.1k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure18.6Interest expense, Q1 FY2026, three months to 2026-03-31$18.6k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure18.8Interest expense, Q2 FY2026, three months to 2026-06-30$18.8k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Net income$k(1,754)Net income, period not labelled, three months to 2024-03-31−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(961)Net income, period not labelled, three months to 2024-06-30−$961.2k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(601)Net income, period not labelled, three months to 2024-09-30−$601.4k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(230)Net income, period not labelled, three months to 2024-12-31−$229.8k. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(328)Net income, Q1 FY2025, three months to 2025-03-31−$327.5k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure113Net income, Q2 FY2025, three months to 2025-06-30$113.3k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(1,823)Net income, Q3 FY2025, three months to 2025-09-30−$1.8m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(8,169)Net income, Q4 FY2025, three months to 2025-12-31−$8.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(1,124)Net income, Q1 FY2026, three months to 2026-03-31−$1.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(1,407)Net income, Q2 FY2026, three months to 2026-06-30−$1.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Diluted EPS$ per share(2.47)Diluted EPS, period not labelled, three months to 2024-03-31−$2.47 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure(0.05)Diluted EPS, period not labelled, three months to 2024-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure(0.03)Diluted EPS, period not labelled, three months to 2024-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figurenot reported(0.02)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure0.00Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(0.07)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figurenot reported(0.03)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(0.03)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Basic EPS$ per share(2.47)Basic EPS, period not labelled, three months to 2024-03-31−$2.47 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure(0.05)Basic EPS, period not labelled, three months to 2024-06-30−$0.05 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure(0.03)Basic EPS, period not labelled, three months to 2024-09-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figurenot reported(0.02)Basic EPS, Q1 FY2025, three months to 2025-03-31−$0.02 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure0.00Basic EPS, Q2 FY2025, three months to 2025-06-30$0.00 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(0.07)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.07 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figurenot reported(0.03)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(0.03)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.03 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure

Balance sheet

Cash and equivalents$3.0m, Q2 FY2026
Shareholders' equity$300.6k, Q2 FY2026
Liminatus Pharma, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$mnot reportednot reportednot reportednot reported0.1Cash and equivalents, period not labelled, at 2024-12-31$56.3k. XBRL concept us-gaap:Cash. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figurenot reported1.3Cash and equivalents, Q2 FY2025, at 2025-06-30$1.3m. XBRL concept us-gaap:Cash. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure0.7Cash and equivalents, Q3 FY2025, at 2025-09-30$724.5k. XBRL concept us-gaap:Cash. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure0.3Cash and equivalents, FY2025, at 2025-12-31$337.7k. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure1.9Cash and equivalents, Q1 FY2026, at 2026-03-31$1.9m. XBRL concept us-gaap:Cash. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure3.0Cash and equivalents, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:Cash. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Current assets$mnot reportednot reportednot reportednot reported5.3Current assets, period not labelled, at 2024-12-31$5.3m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figurenot reported1.8Current assets, Q2 FY2025, at 2025-06-30$1.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure1.2Current assets, Q3 FY2025, at 2025-09-30$1.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure0.5Current assets, FY2025, at 2025-12-31$500.6k. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure2.8Current assets, Q1 FY2026, at 2026-03-31$2.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure3.4Current assets, Q2 FY2026, at 2026-06-30$3.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Total assets$mnot reportednot reportednot reportednot reported5.4Total assets, period not labelled, at 2024-12-31$5.4m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figurenot reported1.9Total assets, Q2 FY2025, at 2025-06-30$1.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure1.3Total assets, Q3 FY2025, at 2025-09-30$1.3m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure0.5Total assets, FY2025, at 2025-12-31$512.8k. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure2.8Total assets, Q1 FY2026, at 2026-03-31$2.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure3.4Total assets, Q2 FY2026, at 2026-06-30$3.4m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Current liabilities$mnot reportednot reportednot reportednot reported24.7Current liabilities, period not labelled, at 2024-12-31$24.7m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figurenot reported10.5Current liabilities, Q2 FY2025, at 2025-06-30$10.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure2.9Current liabilities, Q3 FY2025, at 2025-09-30$2.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure10.3Current liabilities, FY2025, at 2025-12-31$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure2.9Current liabilities, Q1 FY2026, at 2026-03-31$2.9m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure3.0Current liabilities, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Total liabilities$mnot reportednot reportednot reportednot reported24.7Total liabilities, period not labelled, at 2024-12-31$24.7m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figure0.0Total liabilities, Q1 FY2025, at 2025-03-31$1.1k. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure10.7Total liabilities, Q2 FY2025, at 2025-06-30$10.7m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure3.0Total liabilities, Q3 FY2025, at 2025-09-30$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure10.3Total liabilities, FY2025, at 2025-12-31$10.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure2.9Total liabilities, Q1 FY2026, at 2026-03-31$2.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure3.1Total liabilities, Q2 FY2026, at 2026-06-30$3.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Short-term borrowings$mnot reportednot reportednot reportednot reported20.0Short-term borrowings, period not labelled, at 2024-12-31$20.0m. XBRL concept us-gaap:ShortTermBorrowings. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figurenot reported1.4Short-term borrowings, Q2 FY2025, at 2025-06-30$1.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure1.4Short-term borrowings, Q3 FY2025, at 2025-09-30$1.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure1.4Short-term borrowings, FY2025, at 2025-12-31$1.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure1.4Short-term borrowings, Q1 FY2026, at 2026-03-31$1.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure1.4Short-term borrowings, Q2 FY2026, at 2026-06-30$1.4m. XBRL concept us-gaap:ShortTermBorrowings. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure
Shareholders' equity$m(15.8)Shareholders' equity, period not labelled, at 2023-12-31−$15.8m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001104659-26-037933.Report this figure(17.5)Shareholders' equity, period not labelled, at 2024-03-31−$17.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(18.5)Shareholders' equity, period not labelled, at 2024-06-30−$18.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(19.1)Shareholders' equity, period not labelled, at 2024-09-30−$19.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(19.3)Shareholders' equity, period not labelled, at 2024-12-31−$19.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(19.7)Shareholders' equity, Q1 FY2025, at 2025-03-31−$19.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(8.8)Shareholders' equity, Q2 FY2025, at 2025-06-30−$8.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(1.6)Shareholders' equity, Q3 FY2025, at 2025-09-30−$1.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure(9.8)Shareholders' equity, FY2025, at 2025-12-31−$9.8m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure(0.1)Shareholders' equity, Q1 FY2026, at 2026-03-31−$132.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure0.3Shareholders' equity, Q2 FY2026, at 2026-06-30$300.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure

Cash flow

Operating cash flow−$970.0k, Q2 FY2026
Capital expenditure$0, Q4 FY2025
Liminatus Pharma, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30period not labelled2024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k0.0Operating cash flow, period not labelled, three months to 2024-03-31$0. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure(1,104)Operating cash flow, period not labelled, three months to 2024-06-30−$1.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-06, accession 0001104659-25-096872. Derived: 6-month figure less the 3-month figure.Report this figure(206)Operating cash flow, period not labelled, three months to 2024-09-30−$206.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-111651. Derived: 9-month figure less the 6-month figure.Report this figure(141)Operating cash flow, period not labelled, three months to 2024-12-31−$140.7k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(159)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$159.4k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(8,816)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$8.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097304. Derived: 6-month figure less the 3-month figure.Report this figure(601)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$600.6k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-14, accession 0001104659-25-111651. Derived: 9-month figure less the 6-month figure.Report this figure(387)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$386.8k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figure(2,015)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$2.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure(970)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$970.0k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001104659-26-097304. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$knot reportednot reportednot reportednot reportednot reportednot reportednot reported0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-03-31, accession 0001104659-26-037933. Derived: 12-month figure less the 9-month figure.Report this figurenot reportednot reported

Shares

Diluted shares (weighted)48.40m, Q2 FY2026
Liminatus Pharma, Inc., shares, quarterly
Line itemUnitperiod not labelled2024-03-31period not labelled2024-06-30period not labelled2024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares0.0Diluted shares (weighted), period not labelled, three months to 2024-03-31100 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-06-02, accession 0001410578-25-001388.Report this figure17.5Diluted shares (weighted), period not labelled, three months to 2024-06-3017,500,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-10-06, accession 0001104659-25-096872.Report this figure17.5Diluted shares (weighted), period not labelled, three months to 2024-09-3017,500,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure17.5Diluted shares (weighted), Q1 FY2025, three months to 2025-03-3117,500,000 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure23.3Diluted shares (weighted), Q2 FY2025, three months to 2025-06-3023,301,178 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure27.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3027,007,568 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-14, accession 0001104659-25-111651.Report this figure36.0Diluted shares (weighted), Q1 FY2026, three months to 2026-03-3135,999,589 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-15, accession 0001104659-26-062734.Report this figure48.4Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3048,398,314 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure

Shares outstanding: 67.16mShares outstanding, period not labelled, at 2026-08-1467,160,362 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001104659-26-097304.Report this figure at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.